Alafair Biosciences has developed the VersaWrap family of surgical products, with VersaWrap™ Tendon Protector (VersaWrap™ TP) recently cleared by the FDA. VersaWrap TP is indicated for management and protection of tendon injuries where there has been no substantial loss of tendon tissue. The company plans to launch VersaWrap TP directly and through partnerships with major medical device companies. Alafair intends to use new funding to aggressively expand sales and marketing efforts and to broaden and accelerate pipeline product development. The company is Austin-based and privately held. Its board now includes ATP Fund managing partner Kyle Cox following the financing. Alafair is developing a film made from naturally occurring sugar molecules intended to keep tissues and organs separate while they heal, targeting post-surgical adhesions. The company says its product is similar to Genzyme’s Seprafilm but offers better handling, greater robustness, elasticity and conformability. It is conducting pilot animal studies and developing additional product formulations while exploring both European and FDA regulatory pathways. Financially, the company has been funded by research grants, including a $104,000 SBIR grant from the NIH. A recent regulatory filing shows it collected a $525,000 equity investment and could raise another $125,000. Alafair was formed in 2011 with technology licensed from the University of Texas and is headed by Dr. Daniel Peterson in Austin, Texas.

Total raised

$3M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2016